This page has only limited features, please log in for full access.
Chloé Dimeglio; Fabrice Herin; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Marcel Miedougé; Jacques Izopet. Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine. Clinical Infectious Diseases 2021, 1 .
AMA StyleChloé Dimeglio, Fabrice Herin, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin-Blondel, Marcel Miedougé, Jacques Izopet. Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine. Clinical Infectious Diseases. 2021; ():1.
Chicago/Turabian StyleChloé Dimeglio; Fabrice Herin; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Marcel Miedougé; Jacques Izopet. 2021. "Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine." Clinical Infectious Diseases , no. : 1.
Chloé Dimeglio; Fabrice Herin; Marcel Miedougé; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet. One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection. Journal of Infection 2021, 83, 381 -412.
AMA StyleChloé Dimeglio, Fabrice Herin, Marcel Miedougé, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin-Blondel, Jean-Marc Soulat, Jacques Izopet. One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection. Journal of Infection. 2021; 83 (3):381-412.
Chicago/Turabian StyleChloé Dimeglio; Fabrice Herin; Marcel Miedougé; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet. 2021. "One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection." Journal of Infection 83, no. 3: 381-412.
The SARS-CoV-2 virus has spread world-wide since December 2019, killing more than 2.9 million of people. We have adapted a statistical model from the SIR epidemiological models to predict the spread of SARS-CoV-2 in France. Our model is based on several parameters and assumed a 4.2% seroprevalence in Occitania after the first lockdown. The recent use of serological tests to measure the effective seroprevalence of SARS-CoV-2 in the population of Occitania has led to a seroprevalence around 2.4%. This implies to review the parameters of our model to conclude at a lower than expected virus transmission rate, which may be due to infectivity varying with the patient’s symptoms or to a constraint due to an uneven population geographical distribution.
Chloé Dimeglio; Jean-Michel Loubes; Marcel Miedougé; Fabrice Herin; Jean-Marc Soulat; Jacques Izopet. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. Scientific Reports 2021, 11, 1 -5.
AMA StyleChloé Dimeglio, Jean-Michel Loubes, Marcel Miedougé, Fabrice Herin, Jean-Marc Soulat, Jacques Izopet. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. Scientific Reports. 2021; 11 (1):1-5.
Chicago/Turabian StyleChloé Dimeglio; Jean-Michel Loubes; Marcel Miedougé; Fabrice Herin; Jean-Marc Soulat; Jacques Izopet. 2021. "The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics." Scientific Reports 11, no. 1: 1-5.
Chloé Dimeglio; Florence Nicot; Marcel Miedougé; Jean-Loup Chappert; Cécile Donnadieu; Jacques Izopet. Influence of age on the spread of SARS-CoV-2 variant B.1.1.7. Journal of Clinical Virology 2021, 141, 104872 .
AMA StyleChloé Dimeglio, Florence Nicot, Marcel Miedougé, Jean-Loup Chappert, Cécile Donnadieu, Jacques Izopet. Influence of age on the spread of SARS-CoV-2 variant B.1.1.7. Journal of Clinical Virology. 2021; 141 ():104872.
Chicago/Turabian StyleChloé Dimeglio; Florence Nicot; Marcel Miedougé; Jean-Loup Chappert; Cécile Donnadieu; Jacques Izopet. 2021. "Influence of age on the spread of SARS-CoV-2 variant B.1.1.7." Journal of Clinical Virology 141, no. : 104872.
The spread of SARS-CoV-2 and the resulting disease COVID-19 has killed over 2.6 million people as of 18 March 2021. We have used a modified susceptible, infected, recovered (SIR) epidemiological model to predict how the spread of the virus in regions of France will vary depending on the proportions of variants and on the public health strategies adopted, including anti-COVID-19 vaccination. The proportion of SARS-CoV-2 variant B.1.1.7, which was not detected in early January, increased to become 60% of the forms of SARS-CoV-2 circulating in the Toulouse urban area at the beginning of February 2021, but there was no increase in positive nucleic acid tests. Our prediction model indicates that maintaining public health measures and accelerating vaccination are efficient strategies for the sustained control of SARS-CoV-2.
Chloé Dimeglio; Marine Milhes; Jean-Michel Loubes; Noémie Ranger; Jean-Michel Mansuy; Pauline Trémeaux; Nicolas Jeanne; Justine Latour; Florence Nicot; Cécile Donnadieu; Jacques Izopet. Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2. Viruses 2021, 13, 898 .
AMA StyleChloé Dimeglio, Marine Milhes, Jean-Michel Loubes, Noémie Ranger, Jean-Michel Mansuy, Pauline Trémeaux, Nicolas Jeanne, Justine Latour, Florence Nicot, Cécile Donnadieu, Jacques Izopet. Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2. Viruses. 2021; 13 (5):898.
Chicago/Turabian StyleChloé Dimeglio; Marine Milhes; Jean-Michel Loubes; Noémie Ranger; Jean-Michel Mansuy; Pauline Trémeaux; Nicolas Jeanne; Justine Latour; Florence Nicot; Cécile Donnadieu; Jacques Izopet. 2021. "Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2." Viruses 13, no. 5: 898.
Since the beginning of the SARS‐CoV‐2 pandemic, health authorities have been advocating for the generalization of non‐pharmaceutical measures to fight the spread of the disease. Such measures such as physical distancing, mask wearing, tightened basic hygiene, quarantine and even curfews are effective to limit the transmission of SARS‐CoV‐2 and to decrease the virus reproductive number R0. At the same time, these measures have had a drastic effect on influenza viruses and RSV, which are currently absent. In contrast and surprisingly, Rhinoviruses continue to circulate but in younger people, unlike in previous years when they were found in all age groups. The effectiveness of non‐pharmaceutical measures is therefore not uniform and depends on the epidemiology of pathogens, their incidence and circulation
Jean‐Michel Mansuy; Maximin Bourcier; Pauline Trémeaux; Chloé Dimeglio; Jacques Izopet. COVID‐19 pandemic period, where are the seasonal viruses? Journal of Medical Virology 2021, 93, 4097 -4098.
AMA StyleJean‐Michel Mansuy, Maximin Bourcier, Pauline Trémeaux, Chloé Dimeglio, Jacques Izopet. COVID‐19 pandemic period, where are the seasonal viruses? Journal of Medical Virology. 2021; 93 (7):4097-4098.
Chicago/Turabian StyleJean‐Michel Mansuy; Maximin Bourcier; Pauline Trémeaux; Chloé Dimeglio; Jacques Izopet. 2021. "COVID‐19 pandemic period, where are the seasonal viruses?" Journal of Medical Virology 93, no. 7: 4097-4098.
The spread of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and the resulting disease COVID‐19 has killed over 2 million people as of 22 January 2021. We have used a modified susceptible, infected, recovered epidemiological model to predict how the spread of the virus in France will vary depending on the public health strategies adopted, including anti‐COVID‐19 vaccination. Our prediction model indicates that the French authorities' adoption of a gradual release from lockdown could lead in March 2021 to a virus prevalence similar to that before lockdown. However, a massive vaccination campaign initiated in January 2021 and the continuation of public health measures over several months could curb the spread of virus and thus relieve the load on hospitals.
Chloé Dimeglio; Marcel Miedougé; Jean‐Michel Loubes; Jean‐Michel Mansuy; Jacques Izopet. Estimating the impact of public health strategies on the spread of SARS‐CoV‐2: Epidemiological modelling for Toulouse, France. Reviews in Medical Virology 2021, e2224 .
AMA StyleChloé Dimeglio, Marcel Miedougé, Jean‐Michel Loubes, Jean‐Michel Mansuy, Jacques Izopet. Estimating the impact of public health strategies on the spread of SARS‐CoV‐2: Epidemiological modelling for Toulouse, France. Reviews in Medical Virology. 2021; ():e2224.
Chicago/Turabian StyleChloé Dimeglio; Marcel Miedougé; Jean‐Michel Loubes; Jean‐Michel Mansuy; Jacques Izopet. 2021. "Estimating the impact of public health strategies on the spread of SARS‐CoV‐2: Epidemiological modelling for Toulouse, France." Reviews in Medical Virology , no. : e2224.
Summary The spread of SARS-CoV-2 and the resulting disease Covid-19 has killed over 2 million people as of January 22, 2021. We have designed a model and used it to quantify the effect of a 6 p.m curfew on the SARS-CoV-2 epidemic in Toulouse, France. The data show that this measure can lead to the opposite effect from that intended due to larger groups of people on the authorized hours.
Chloé Dimeglio; Marcel Miedougé; Jean-Michel Loubes; Jean-Michel Mansuy; Jacques Izopet. Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France. Journal of Infection 2021, 82, 186 -230.
AMA StyleChloé Dimeglio, Marcel Miedougé, Jean-Michel Loubes, Jean-Michel Mansuy, Jacques Izopet. Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France. Journal of Infection. 2021; 82 (5):186-230.
Chicago/Turabian StyleChloé Dimeglio; Marcel Miedougé; Jean-Michel Loubes; Jean-Michel Mansuy; Jacques Izopet. 2021. "Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France." Journal of Infection 82, no. 5: 186-230.
Chloé Dimeglio; Fabrice Herin; Marcel Miedougé; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet. Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection. Clinical Infectious Diseases 2021, 1 .
AMA StyleChloé Dimeglio, Fabrice Herin, Marcel Miedougé, Guillaume Martin-Blondel, Jean-Marc Soulat, Jacques Izopet. Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection. Clinical Infectious Diseases. 2021; ():1.
Chicago/Turabian StyleChloé Dimeglio; Fabrice Herin; Marcel Miedougé; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet. 2021. "Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection." Clinical Infectious Diseases , no. : 1.
The role and performance of chest CT in the diagnosis of the coronavirus disease 2019 pandemic remains under active investigation. A recent case report in this journal found that a COVID‐19 diagnosis has been made from the serological results despite first CT scan and RT‐PCR negative results. We have included 311 consecutive patients with COVID‐19‐like symptoms who underwent a RT‐PCR test on nasopharyngeal swab samples and a chest CT scan. Patients with a positive chest scan and a negative RT‐PCR were screened for serum total anti‐SARS‐CoV‐2 antibodies 2 months after the onset of symptoms using the Wantai test in order to arbitrate between RT‐PCR and CT scans discordant results. Most of the RT‐PCR and chest CT results agreed but the serological tests indicate that most CT positive/NAT negative patients are not infected by SARS‐CoV‐2 and alternative diagnoses should be seriously considered.
Chloé Dimeglio; Samia Collot; Florence Abravanel; Karine Sauné; Sébastien Lhomme; Marie Faruch; Nicolas Sans; Jacques Izopet. Diagnosis options in patients suffering from COVID‐19‐like symptoms. Journal of Medical Virology 2020, 93, 4076 -4077.
AMA StyleChloé Dimeglio, Samia Collot, Florence Abravanel, Karine Sauné, Sébastien Lhomme, Marie Faruch, Nicolas Sans, Jacques Izopet. Diagnosis options in patients suffering from COVID‐19‐like symptoms. Journal of Medical Virology. 2020; 93 (7):4076-4077.
Chicago/Turabian StyleChloé Dimeglio; Samia Collot; Florence Abravanel; Karine Sauné; Sébastien Lhomme; Marie Faruch; Nicolas Sans; Jacques Izopet. 2020. "Diagnosis options in patients suffering from COVID‐19‐like symptoms." Journal of Medical Virology 93, no. 7: 4076-4077.
A recent study in this journal reported characteristics of healthcare workers (HCW) infected with SARS-CoV-2 in order to identify new cases as early as possible.1Jary A. Flandre P. Chabouis A. et al.Clinical presentation of Covid-19 in health care workers from a French University Hospital.J Infect. 2020; 81: e61-e63Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar Here, we aimed to determine the serological status of HCW after the first wave of the epidemic, and the extent of their protective immunity. This is particularly important as this population will always be in the front line combatting the probable continuation of the present epidemic.2Pollán M. Pérez-Gómez B. Pastor-Barriuso R. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.Lancet. 2020; Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar,3Stringhini S. Wisniak A. Piumatti G. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.Lancet. 2020; Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar HCW can also be a source of transmission, introducing virus into a hospital harbouring many susceptible patients or co-workers.
Chloé Dimeglio; Fabrice Herin; Marcel Miedougé; Jean-Pierre Cambus; Florence Abravanel; Jean-Michel Mansuy; Jean-Marc Soulat; Jacques Izopet. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. Journal of Infection 2020, 82, e29 -e32.
AMA StyleChloé Dimeglio, Fabrice Herin, Marcel Miedougé, Jean-Pierre Cambus, Florence Abravanel, Jean-Michel Mansuy, Jean-Marc Soulat, Jacques Izopet. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. Journal of Infection. 2020; 82 (1):e29-e32.
Chicago/Turabian StyleChloé Dimeglio; Fabrice Herin; Marcel Miedougé; Jean-Pierre Cambus; Florence Abravanel; Jean-Michel Mansuy; Jean-Marc Soulat; Jacques Izopet. 2020. "Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France." Journal of Infection 82, no. 1: e29-e32.
Marion Migueres; Catherine Mengelle; Chloé Dimeglio; Alain Didier; Muriel Alvarez; Pierre Delobel; Jean-Michel Mansuy; Jacques Izopet. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. Journal of Clinical Virology 2020, 130, 104580 -104580.
AMA StyleMarion Migueres, Catherine Mengelle, Chloé Dimeglio, Alain Didier, Muriel Alvarez, Pierre Delobel, Jean-Michel Mansuy, Jacques Izopet. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. Journal of Clinical Virology. 2020; 130 ():104580-104580.
Chicago/Turabian StyleMarion Migueres; Catherine Mengelle; Chloé Dimeglio; Alain Didier; Muriel Alvarez; Pierre Delobel; Jean-Michel Mansuy; Jacques Izopet. 2020. "Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers." Journal of Clinical Virology 130, no. : 104580-104580.
We investigated the seroprevalence and incidence of hepatitis E virus (HEV) infection in men who have sex with men (MSM) who have been exposed to pre‐exposure prophylaxis (PrEP) against HIV as sexual transmission of HEV has been suggested. A total of 147 PrEP‐using MSM and 147 blood donors matched for sex, age and geographical area were tested for anti‐HEV IgG and IgM. Among them, 135 have been followed for 1 year, at the end of which serological tests for HEV were performed retrospectively on stored samples. Laboratory data on sexual transmitted infections (STIs) and viral hepatitis, including hepatitis A virus (HAV), were collected. Baseline seroprevalence rates in PrEP users were 42.2% (anti‐HEV IgG) and 3.4% (anti‐HEV IgM). Those of the control blood donors were similar (anti‐HEV IgG 43.5% and anti‐HEV IgM 4.1%). There was no incident of HEV infection despite the rates of bacterial STIs (incidence rate (IR) = 46.6%) and HAV infection (IR=15.8%). Age was the only risk factor associated with anti‐HEV IgG seropositivity at baseline and at the end of follow‐up. Sexual transmission does not seem to be a major route of HEV infection in MSM, unlike HAV.
Marion Migueres; Maïlys Ducours; Chloé DiMeglio; Pascale Trimoulet; Florence Abravanel; Pierre Delobel; Charles Cazanave; Jacques Izopet. No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis. Journal of Viral Hepatitis 2020, 27, 1495 -1501.
AMA StyleMarion Migueres, Maïlys Ducours, Chloé DiMeglio, Pascale Trimoulet, Florence Abravanel, Pierre Delobel, Charles Cazanave, Jacques Izopet. No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis. Journal of Viral Hepatitis. 2020; 27 (12):1495-1501.
Chicago/Turabian StyleMarion Migueres; Maïlys Ducours; Chloé DiMeglio; Pascale Trimoulet; Florence Abravanel; Pierre Delobel; Charles Cazanave; Jacques Izopet. 2020. "No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis." Journal of Viral Hepatitis 27, no. 12: 1495-1501.
The SARS-CoV-2 virus has spread world-wide since December 2019, affecting millions of people and killing thousands. The recent use of serological tests to measure the effective seroprevalence of SARS-CoV-2 in the general population has led us to assess the consequences of a much lower than expected seroprevalence on the real dynamics of the virus in the population. Our prediction models assumed a 4.2% seroprevalence in Occitania and it has turned out to be only 1.3% (CI 95%: 0.6% - 2.6%, binomial method). This implies a lower than expected virus transmission rate , which may be due to infectivity varying with the patient’s symptoms or to a constraint due to an uneven population geographical distribution.
Chloe DiMeglio; Jean-Michel Loubes; Marcel Miedougé; Fabrice Herin; Jean-Marc Soulat; Jacques Izopet. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. 2020, 1 .
AMA StyleChloe DiMeglio, Jean-Michel Loubes, Marcel Miedougé, Fabrice Herin, Jean-Marc Soulat, Jacques Izopet. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. . 2020; ():1.
Chicago/Turabian StyleChloe DiMeglio; Jean-Michel Loubes; Marcel Miedougé; Fabrice Herin; Jean-Marc Soulat; Jacques Izopet. 2020. "The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics." , no. : 1.
Chloé Dimeglio; Jean-Michel Mansuy; Sandrine Charpentier; Isabelle Claudet; Jacques Izopet. Children are protected against SARS-CoV-2 infection. Journal of Clinical Virology 2020, 128, 104451 -104451.
AMA StyleChloé Dimeglio, Jean-Michel Mansuy, Sandrine Charpentier, Isabelle Claudet, Jacques Izopet. Children are protected against SARS-CoV-2 infection. Journal of Clinical Virology. 2020; 128 ():104451-104451.
Chicago/Turabian StyleChloé Dimeglio; Jean-Michel Mansuy; Sandrine Charpentier; Isabelle Claudet; Jacques Izopet. 2020. "Children are protected against SARS-CoV-2 infection." Journal of Clinical Virology 128, no. : 104451-104451.
Summary A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy.
Chloé Dimeglio; Jean-Michel Loubes; Benjamin Deporte; Martine Dubois; Justine Latour; Jean-Michel Mansuy; Jacques Izopet. The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. Journal of Infection 2020, 81, 318 -356.
AMA StyleChloé Dimeglio, Jean-Michel Loubes, Benjamin Deporte, Martine Dubois, Justine Latour, Jean-Michel Mansuy, Jacques Izopet. The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. Journal of Infection. 2020; 81 (2):318-356.
Chicago/Turabian StyleChloé Dimeglio; Jean-Michel Loubes; Benjamin Deporte; Martine Dubois; Justine Latour; Jean-Michel Mansuy; Jacques Izopet. 2020. "The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France." Journal of Infection 81, no. 2: 318-356.
Background Obesity surgery has proven its effectiveness in weight loss. However, after a loss phase of about 12 to 18 months, between 20% and 40% of patients regain weight. Prediction of weight evolution is therefore useful for early detection of weight regain. Objective This proof-of-concept study aimed to analyze the postoperative weight trajectories and to identify “curve families” for early prediction of weight regain. Methods This was a monocentric retrospective study with calculation of the weight trajectory of patients having undergone gastric bypass surgery. Data on 795 patients after a 2-year follow-up allowed modeling of weight trajectories according to a hierarchical cluster analysis (HCA) tending to minimize the intragroup distance according to Ward. Clinical judgement was used to finalize the identification of clinically relevant representative trajectories. This modeling was validated on a group of 381 patients for whom the observed weight at 18 months was compared to the predicted weight. Results Two successive HCA produced 14 representative trajectories, distributed among 4 clinically relevant families: Of the 14 weight trajectories, 6 decreased systematically over time or decreased and then stagnated; 4 decreased, increased, and then decreased again; 2 decreased and then increased; and 2 stagnated at first and then began to decrease. A comparison of observed weight and that estimated by modeling made it possible to correctly classify 98% of persons with excess weight loss (EWL) >50% and more than 58% of persons with EWL between 25% and 50%. In the category of persons with EWL >50%, weight data over the first 6 months were adequate to correctly predict the observed result. Conclusions This modeling allowed correct classification of persons with EWL >50% and could identify early after surgery the patients with potentially less that optimal weight loss. Further studies are needed to validate this model in other populations, with other types of surgery, and with other medical-surgical teams.
Chloe DiMeglio; Guillaume Becouarn; Philippe Topart; Rodolphe Bodin; Jean Christophe Buisson; Patrick Ritz. Weight Loss Trajectories After Bariatric Surgery for Obesity: Mathematical Model and Proof-of-Concept Study. JMIR Medical Informatics 2020, 8, e13672 .
AMA StyleChloe DiMeglio, Guillaume Becouarn, Philippe Topart, Rodolphe Bodin, Jean Christophe Buisson, Patrick Ritz. Weight Loss Trajectories After Bariatric Surgery for Obesity: Mathematical Model and Proof-of-Concept Study. JMIR Medical Informatics. 2020; 8 (3):e13672.
Chicago/Turabian StyleChloe DiMeglio; Guillaume Becouarn; Philippe Topart; Rodolphe Bodin; Jean Christophe Buisson; Patrick Ritz. 2020. "Weight Loss Trajectories After Bariatric Surgery for Obesity: Mathematical Model and Proof-of-Concept Study." JMIR Medical Informatics 8, no. 3: e13672.
Hepatitis E virus (HEV) infection causes chronic hepatitis in solid organ transplant (SOT) recipients. Antiviral therapy consists of three months of ribavirin, although response rates are not optimal. We characterized plasma HEV kinetic patterns in 41 SOT patients during ribavirin therapy. After a median pharmacological delay of three (range: 0–21) days, plasma HEV declined from a median baseline level of 6.12 (3.53–7.45) log copies/mL in four viral kinetic patterns: (i) monophasic (n = 18), (ii) biphasic (n = 13), (iii) triphasic (n = 8), and (iv) flat-partial response (n = 2). The mean plasma HEV half-life was estimated to be 2.0 ± 0.96 days. Twenty-five patients (61%) had a sustained virological response (SVR) 24 weeks after completion of therapy. Viral kinetic patterns (i)–(iii) were not associated with baseline characteristics or outcome of therapy. A flat-partial response was associated with treatment failure. All patients with a log concentration decrease of plasma HEV at day seven of >15% from baseline achieved SVR. In conclusion, viral kinetic modeling of plasma HEV under ribavirin therapy showed, for the first time, four distinct kinetic profiles, a median pharmacologic delay of three days, and an estimated HEV half-life of two days. Viral kinetic patterns were not associated with response to therapy, with the exception of a flat-partial response.
Sebastien Lhomme; Swati Debroy; Nassim Kamar; Florence Abravanel; David Metsu; Olivier Marion; Chloé DiMeglio; Scott J. Cotler; Jacques Izopet; Harel Dahari. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses 2019, 11, 630 .
AMA StyleSebastien Lhomme, Swati Debroy, Nassim Kamar, Florence Abravanel, David Metsu, Olivier Marion, Chloé DiMeglio, Scott J. Cotler, Jacques Izopet, Harel Dahari. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses. 2019; 11 (7):630.
Chicago/Turabian StyleSebastien Lhomme; Swati Debroy; Nassim Kamar; Florence Abravanel; David Metsu; Olivier Marion; Chloé DiMeglio; Scott J. Cotler; Jacques Izopet; Harel Dahari. 2019. "Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin." Viruses 11, no. 7: 630.
Hepatitis E virus infection is a significant public health problem in many parts of the world including Africa. We tested serum samples from 900 patients in Burkina Faso presenting with febrile icterus. They all tested negative for yellow fever, but those from 23/900 (2.6%) patients contained markers of acute HEV infection (anti-HEV IgM and HEV RNA positive). Genotyping indicated that 14 of the strains were HEV genotype 2b. There was an overall HEV IgG seroprevalence of 18.2% (164/900). In a bivariate analysis, the factors linked to HEV exposure were climate and patient age. Older patients and those living in arid regions were more likely to have HEV infection. HEV genotype 2b circulating only in humans can be involved in some acute febrile icterus cases in Burkina Faso. Better access to safe water, sanitation, and improved personal hygiene should improve control of HEV infection in this country.
Chloé DiMeglio; Dramane Kania; Judith Mbombi Mantono; Thérèse Kagoné; Sylvie Zida; Souleymane Tassembedo; Amadou Dicko; Bachirou Tinto; Seydou Yaro; Hervé Hien; Jérémi Rouamba; Brice Bicaba; Isaïe Medah; Nicolas Meda; Oumar Traoré; Edouard Tuaillon; Florence Abravanel; Jacques Izopet. Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso. Viruses 2019, 11, 554 .
AMA StyleChloé DiMeglio, Dramane Kania, Judith Mbombi Mantono, Thérèse Kagoné, Sylvie Zida, Souleymane Tassembedo, Amadou Dicko, Bachirou Tinto, Seydou Yaro, Hervé Hien, Jérémi Rouamba, Brice Bicaba, Isaïe Medah, Nicolas Meda, Oumar Traoré, Edouard Tuaillon, Florence Abravanel, Jacques Izopet. Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso. Viruses. 2019; 11 (6):554.
Chicago/Turabian StyleChloé DiMeglio; Dramane Kania; Judith Mbombi Mantono; Thérèse Kagoné; Sylvie Zida; Souleymane Tassembedo; Amadou Dicko; Bachirou Tinto; Seydou Yaro; Hervé Hien; Jérémi Rouamba; Brice Bicaba; Isaïe Medah; Nicolas Meda; Oumar Traoré; Edouard Tuaillon; Florence Abravanel; Jacques Izopet. 2019. "Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso." Viruses 11, no. 6: 554.
A fraction of plasma donations undergoes hepatitis E virus (HEV) RNA screening since late 2014 in France. The aim of this study was to determine the frequency of HEV RNA as well as the viral load and the evolution of genotype distribution over a 3-year period (2015-2017) in asymptomatic blood donors in comparison with symptomatic patients routinely diagnosed. The overall detection rate of HEV RNA in plasma donations was 0.10% during the 3-year period, with a median viral load of 717 IU/mL (range: <60-168 000 IU/mL) in the 189 samples found HEV RNA positive. One hundred and twenty samples (64.4%) were successfully HEV genotyped. Most strains were HEV3f (n = 54; 44.3%) and HEV3c (n = 46; 37.7%). The genotype distribution was not different throughout the 3-year period and we found no association between the genotype and where the blood donors lived (P = 0.96). The HEV genotype distributions in infected blood donors and symptomatic patients were similar. However, the symptomatic patients had a higher viral load (median 282 000 IU/mL; range: <60-136 000 000 IU/mL; P < 0.01) than the blood donors. Overall, asymptomatic blood donors and patients with symptomatic hepatitis E had similar genotype distributions but the blood donors had lower viral loads.
Sebastien Lhomme; Pierre Gallian; Chloé DiMeglio; Azzedine Assal; Florence Abravanel; Pierre Tiberghien; Jacques Izopet. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. Journal of Viral Hepatitis 2019, 26, 1139 -1142.
AMA StyleSebastien Lhomme, Pierre Gallian, Chloé DiMeglio, Azzedine Assal, Florence Abravanel, Pierre Tiberghien, Jacques Izopet. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. Journal of Viral Hepatitis. 2019; 26 (9):1139-1142.
Chicago/Turabian StyleSebastien Lhomme; Pierre Gallian; Chloé DiMeglio; Azzedine Assal; Florence Abravanel; Pierre Tiberghien; Jacques Izopet. 2019. "Viral load and clinical manifestations of hepatitis E virus genotype 3 infections." Journal of Viral Hepatitis 26, no. 9: 1139-1142.